Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation.
暂无分享,去创建一个
J. Ritz | R. Soiffer | E. Weller | E. Alyea | S. Lee | Edie Weller | J. Ritz | Stephanie J. Lee
[1] A. Hunter,et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Pearlman,et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Singer,et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.
[4] R. Negrin,et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. , 1994, Blood.
[5] W. Velasquez,et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Horowitz,et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.
[7] D. Cunningham,et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. , 1993, Bone marrow transplantation.
[8] J. Singer,et al. Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation [letter] , 1993 .
[9] J. Nemunaitis,et al. Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation. , 1993, Blood.
[10] A. Freedman,et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. , 1992, Journal of Clinical Oncology.
[11] J. Nemunaitis,et al. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. , 1992, Blood.
[12] W. Fibbe,et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. , 1992, Blood.
[13] R. Advani,et al. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma , 1992, Annals of Internal Medicine.
[14] J. Nemunaitis,et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. , 1991, Blood.
[15] C. Tiley,et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial , 1990, The Lancet.
[16] J. Ritz,et al. Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. , 1986, Transplantation.
[17] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.